VERTEX Vows To moVE fasT on nEw DRUG DEaL
THE boss of US pharmaceutical giant Vertex has written to the Daily Express to stress its commitment to agreeing a deal for its upcoming Trikafta drug.
Concerned John Binns, 71, had written to Vertex’s Dr Jeff Leiden to thank him after his cystic fibrosis-suffering grandson Tristan Scott-Binns, nine, finally got Orkambi.
The lad is being raised by his grandparents after his dad Andrew died after suffering depression and his uncle Adam, 25, died from CF.
This week, Dr Leiden replied to us, saying: “We are committed to ensuring people living with CF in the UK have access to our medicines. We are working with a sense of urgency to make it happens as soon as possible.”
Vertex’s current CF drugs Orkambi and Symkevi are suitable for 50 per cent of patients but Trikafta is better and suitable for 90 per cent of CF-ers.
The European Medicines Agency is processing its licence for Trikafta. Dr Leiden added: “We will do all we can to move quickly and be collaborative with NHS England and NICE.”